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Background: Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of unknown aetiology
and poor prognosis, characterized by altered tissue repair and fibrosis. The extracellular matrix (ECM) is a critical
component in regulating cellular homeostasis and appropriate wound healing. The aim of our study was to
determine the expression profile of highlighted ECM proteins in IPF lungs.
Methods: ECM gene and protein expression was analyzed by cDNA microarrays, rt-PCR, immunohistochemistry and
western-blot in lungs from idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis (HP), categorized as
chronic (cHP) and subacute (saHP), and healthy lung tissue. Primary fibroblast cultures from normal subjects and
fibrotic patients were studied to evaluate tenascin-C (TNC) synthesis.
Results: A total of 20 ECM proteins were upregulated and 6 proteins downregulated in IPF. TNC was almost
undetected in normal lungs and significantly upregulated in fibrotic lungs (IPF and cHP) compared to saHP.
Furthermore, it was located specifically in the fibroblastic foci areas of the fibrotic lung with a subepithelial gradient
pattern. TNC levels were correlated with fibroblastic foci content in cHP lungs. Versican and fibronectin
glycoproteins were associated with TNC, mainly in fibroblastic foci of fibrotic lungs. Fibroblasts from IPF patients
constitutively synthesized higher levels of TNC than normal fibroblasts. TNC and α-sma was induced by TGF-β1 in
both fibrotic and normal fibroblasts. TNC treatment of normal and fibrotic fibroblasts induced a non-significant
increased α-sma mRNA.
Conclusions: The difference in ECM glycoprotein content in interstitial lung diseases could contribute to the
development of lung fibrosis. The increase of TNC in interstitial areas of fibrotic activity could play a key role in
the altered wound healing.
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Idiopathic pulmonary fibrosis (IPF) is the most common
and lethal lung fibrotic process [1]. The histological defined
pattern is the usual interstitial pneumonia (UIP) character-
ized by the loss of epithelial structures, the appearance
of interstitial fibrosis, microscopic honeycombing and
focal areas of fibroblast-myofibroblast aggregates termed* Correspondence: mariamolinamolina@hotmail.com
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unless otherwise stated.“fibroblastic foci”. These foci are associated with poor
prognosis of disease and contain several hallmarks of the
reactive stroma [2]. This stroma exhibits an excessive de-
position of extracellular matrix (ECM) components, such
us collagen I, collagen III and structural glycoproteins and
proteoglycans.
During the last few years, there has been an increased
interest in the role of glycoproteins and proteoglycans
in the pathological process of altered wound healing.
Tenascin C (TNC) is a large hexameric ECM glycoprotein
that is specifically and transiently expressed upon tissue
injury; it is activated after local injury and down-regulatedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0) which permits unrestricted use, distribution, and
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role in cell adhesion, fibroblast migration, and other pro-
cesses related to tissue remodeling and wound healing
[4,5]. Paron and col. [6] showed that TNC was able to
support and promote growth and migration of pancreatic
cancer cells. Other authors have described the association
of TNC expression with the progression and aggression of
cancer [7].
Versican (VCAN), a chondroitin sulfate proteoglycan,
participates in cell adhesion, proliferation, migration and
angiogenesis and hence plays a central role in tissue
morphogenesis and maintenance [8,9]. In addition, this
protein contributes to the development of a number of
pathologic processes including atherosclerotic vascular
diseases, cancer, tendon remodel ng and central nervous
system injury [10].
Fibronectins (FNs) are multifunctional glycoproteins
found in the ECM of several tissues and plasma. Cellular
FN, a multimeric form synthesized by mesenchymal,
epithelial, and inflammatory cells, is deposited in ECM
fibrils and contains variable proportions of the extra type
III domains A and B (EDA and EDB). Muro and col.
[11] showed that EDA-containing FN is essential for the
lung collagen deposition after bleomycin-induced lung
injury in rats, which suggests that EDA-FN would play a
critical role in experimental induced tissue fibrogenesis.
ECM provides not only structural and mechanical
support, but it is also implicated in important biological
functions during tissue remodeling. The abnormal wound
repair and pro-fibrotic activity seem to be crucial in the
progression of lung fibrosis. Since the ECM glycoproteins
are important in the wound healing process, these pro-
teins could be crucial for the development of lung fibrosis
after tissue injury. For this reason, we hypothesized that a
better characterization of the ECM protein expression in
IPF lungs could provide relevant information to under-
stand the progression of this lethal interstitial lung disease
and to open new targets for therapeutic approaches.
The aim of our study was to analyze the lung ECM
proteins in IPF.
Methods
Human tissue samples
Pathological interstitial lung tissue was obtained by lung
video-assisted thoracoscopic surgery from patients under-
going diagnostic evaluation at the Unit of Interstitial Lung
Diseases of the Respiratory Diseases department from
Bellvitge University Hospital (Hospitalet del Llobregat,
Spain) and the Department of Pneumology of Hospital
Clínic de Barcelona (Barcelona, Spain). The diagnosis of
IPF, chronic hypersensitivity pneumonitis (cHP) and sub-
acute hypersensitivity pneumonitis (saHP) was performed
following the ATS/ERS guidelines [1,12], using two
biopsies from different lung lobes after the histologicalevaluation of two expert pathologists in interstitial lung
disease. All cases of IPF fulfilled documented criteria for a
diagnosis of UIP, and patients with cHP presented dif-
ferent degrees of lung fibrosis. In those cases, a scoring
system to determine the extent of fibroblastic foci was
undertaken independently by two pathologists according
to the Brompton scoring method [2], blind to the clinical
or biomolecular data. Healthy lung tissue was obtained
from individuals undergoing surgical treatment for spon-
taneous pneumothorax, without clinical or hystopatholo-
gical evidence of pulmonary disease.
The Ethics Committee of Bellvitge University Hospital
and Hospital Clinic approved the study. Written informed
consent was previously obtained from all individuals ac-
cording to institutional guidelines.
Primary human fibroblast studies
Primary fibroblasts were isolated from normal and IPF
lung tissues, as previously described [13]. Briefly, 1 mm2
fragments of tissue were incubated under sterile conditions
in Dulbecco’s modified Eagle’s media (DMEM) (Gibco,
Grand Island) supplemented with 10% fetal bovine serum
(FBS) (Gibco), 100 IU/ml penicillin (Gibco), 100 μg/ml
streptomycin (Gibco) and 2 μg/ml amphotericin B (Sigma).
Cell cultures were kept in a 5% CO2 humidified atmos-
phere at 37°C. For all experiments, primary lung fibroblasts
were used between passages 3 and 5, and plated at a
density of 2 × 105 cells/well in 6-well culture plates.
When cell culture reached 70% of confluence, cells
were serum starved in DMEM for 24 hours prior to
stimulation with TNC (Millipore, Bedford, MA) at a final
concentration of 10 μg/ml or TGF-β1 at 5 ng/ml (R&D
Systems, Minneapolis, MN), for 4 and 24 hours.
RNA extraction and retrotranscriptase
Lung samples and fibroblast cells were lysed in Trizol
(Invitrogen, Carlsbad, CA) and total RNA was extracted.
After the ethanol precipitation, RNAs were cleaned up
and genomic DNA was eliminated using the RNAeasy
plus Mini kit (Qiagen, Valencia, CA). RNA concentration
and purity was analyzed by UV-spectrophotometry
(NanoDrop, Thermo Scientific). Absorbance ratio A260:
A230 and A260:A280 were greater than 1.7 and 2.0, re-
spectively. If not, an extra ethanol precipitation was per-
formed. For microarray experiments, ribosomal RNA
band integrity was verified on Agilent BioAnalyzer 2100
using an Eukaryote Total Nano Assay. cDNA was syn-
thesised with one microgram of RNA by High Capacity
cDNA Reverse Transcription kit (Applied Biosystems,
Foster City, CA).
Oligonucleotide microarray experiments
The normal RNA pool and the IPF RNA pool were
performed using equal quantities of RNA of 7 normal
Estany et al. BMC Pulmonary Medicine 2014, 14:120 Page 3 of 9
http://www.biomedcentral.com/1471-2466/14/120subjects and 12 patients with IPF, respectively. cDNA
was synthesized with one microgram of each pool.
cDNA microarray of extracellular matrix proteins (Human
Extracellular Matrix and Adhesion Molecules PCR Array,
SABioscience) was made with both pools according to the
manufacturer’s recommendation. The results were ana-
lyzed by the ΔΔCt method.
Reverse transcription real-time PCR
Lungs from 22 patients with fibrotic interstitial lung
disease (ILD) (17 patients with IPF and 5 patients with
cHP), 4 patients with an inflammatory ILD (such as saHP)
and 7 normal subjects were analyzed by quantitative
reverse transcription-polymerase chain reaction (qPCR).
qPCR was performed with taqMan gene expression
master mix (Applied Biosystems) for TNC, VCAN
and EDA-FN. The results were analyzed by the ΔΔCt
method, normalized with two housekeeping genes
(Eukaryotic 18S rRNA and DNA-directed RNA polymer-
ase II) and relative to a common calibrator for every plate.
All samples were run in triplicate.
For primary fibroblast experiments, qPCR for TNC
and α-sma normalized with these two housekeeping
genes were done in the same way.
Western blot
Small pieces of lung samples were homogenized using a
lysis buffer (50 mM Tris, 150 mM NaCl, 1% Igepal, 5 mM
EDTA, 1 mM DTT, 1/1000 protease inhibitor) for 30 min
at 4°C, in an orbital mixer. Protein concentration was
determined using total protein kit quantification (Sigma-
Aldrich).
100 μg protein samples were separated on mini-protean
TGX, 4-15% gel (Bio-Rad, Hercules, CA) in TRIS/GLI-
CINE/SDS Running Buffer (Bio-Rad) and transferred to
nitrocellulose membrane (Bio-Rad). Afterwards, they
were probed with a mouse monoclonal for TNC (1/200;
Abcam, Cambridge, UK), α-sma (1/1000, 1A4, Sigma
Aldrich, St Louis, MO), and β-actin or β-tubulin (1/10000,
Sigma Aldrich, St Louis, MO) overnight. Immunoblots
were incubated with peroxidase-conjugated rabbit anti-
mouse (1/1000 dilution, DakoCytomation) for 1 hour and
developed using SuperSignal West Pico Chemilumines-
cent Substrate (Pierce, Rockford, IL). For Western blot
analysis, the densitometry unit of the protein expression
in control cells was assigned as 1 after normalized with
β-actin.
Immunohistochemistry
Lung samples were fixed in formaldehyde, embedded in
paraffin and serial sections were prepared for cell (alpha-
smooth muscle actin-α-sma cells) and ECM glycoprotein
staining. Tissue sections were deparaffinized, rehydra-
ted and then antigen was retrieved by being boiled inTris-EDTA buffer (pH 9.0) for 5 min. Samples were
blocked with 0,3% H2O2 for 1 h with avidin/biotin block-
ing kit (vector). Immunohistochemistry was carried out
using primary antibody of tenascin C (1/300, Abcam),
versican (1/250, Lifespan) and fibronectin domain EDA
(1/400, Abcam), followed by biotin-avidin/peroxidase
(Vectastain Elite ABC kit) incubation. Alpha-smooth muscle
actin (α-sma) (RTU Flex, Dako) was performed with
Autostainer Link Instrument, using EnVision Flex+,
mouse, and high pH (Link) (Dako), according to the man-
ufacturer’s recommendation. All sections were counter-
stained with haematoxylin.
Statistical methods
Data were analyzed with PASW Statistics version 18.
Relative PCR values were analyzed by Kruskal-Wallis
test to compare more than two groups, and Mann–
Whitney U-test or Wilcoxon Signed Rank Test when
comparing two independent or related samples, respect-
ively. ANOVA with post-hoc analysis, corrected with
Scheffé’s method, was used to compare the TNC, VCAN,
and FN gene expression pairwise between different
groups. The relationship between the semiquantitative%
fibroblast-foci score, FVC and DLCO, and the level of
TNC in fibrotic lungs was analyzed using the Spearman
rank correlation coefficient. Two-tailed p-values lower
than 0.05 or 0.01 were considered significant. To evaluate
linear dependency of numerical variables, Pearson correl-
ation coefficient was calculated.
Results
Subjects
The clinical and functional characteristics of the patients
are presented in Table 1. The mean age for IPF group
was similar to the cHP group, but the saHP and the nor-
mal groups were younger (p = 0.03 and p < 0.001, re-
spectively). Smoking history was present in all studied
groups. Sex distribution was similar among all the
groups, with a predominance of male versus female. The
IPF subjects showed the lowest value of forced vital cap-
acity (FVC) (63% ± 14.6%) when compared with normal
group (91.8% ± 2.4%, p < 0.001), cHP (68% ± 16%, p = 0.5)
and saHP patients (72% ± 17.5%, p = 0.42). The diffusion
lung capacity for carbon monoxide (DLCO) was signifi-
cantly lower in IPF patients (43.5% ± 15.5%), as com-
pared to normal subjects (90.4% ± 3.5%, p < 0.001), but
resulted similar to cHP patients (45.2% ± 18.5%, p = 0.73)
and saHP group (48.4% ± 17.5%, p = 0.8). Changes in
DLCO and FVC over 6 months were significantly differ-
ent between IPF and saHP (Table 1).
Tenascin C upregulation in lung fibrosis
To identify the differences in the ECM protein expres-
sion profile of fibrotic lungs that differ from normal
Table 1 Characteristics of the study groups
Control IPF cHP saHP
Number of subjects 7 17 5 4
Age (years) 40,2 ± 9,8* 62,5 ± 5 59,4 ± 8,2 53,5 ± 0,7*
Male/Female 5/2 12/5 4/1 2/2
Smoking (no/Ex/C) 4/1/2 6/9/2 2/2/1 1/3/0
FVC% pred 91,8 ± 2,4* 63,3 ± 14,2# 73 ± 16,5 72 ± 9,9
DLCO% pred 90,4 ± 3,5* 43,7 ± 15# 45,2 ± 18,5# 48,4 ± 17,5
%FVC change - 3,2 ± 6,2 - 1,9 ± 3,1 - 0,1 ± 2,1*
%DLCO change - 2,9 ± 5,9 - 1,1 ± 3,5 + 0,3 ± 4,5*
Data are presented as mean ± SD. Results were analyzed using t-student test for parametric values or Mann–Whitney Rank Sum test for non-parametric values.
*p < 0,05: significance difference compared with the IPF group; # p < 0,05: significance difference compared with the control group.
No: never smoking; Ex: ex-smoker; C: current smoker; FVC: forced vital capacity; DLCO: diffusion lung capacity for carbon monoxide; IPF: idiopathic pulmonary
fibrosis; cHP: chronic hypersensitivity pneumonitis; saHP: subacute hypersensitivity pneumonitis. %FVC change: Absolute change in percent-predicted FVC over
24 weeks. %DLCO change: Absolute change in percent-predicted DLCO over 24 weeks.
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ECM proteins were tested, 20 of which were more than
2-fold upregulated in fibrotic lungs compared with normal
lungs (Figure 1, Additional file 1). Among them, there
were relevant proteins for the altered wound healing,
such as TNC, VCAN, matrix metalloproteinases (MMPs)
(MMP1, 2, 3, 7, 9, 10, 11, 12, 13, 16), secreted phos-
phoprotein1 (SPP1), integrin alpha7 (ITGA7) and beta3
(ITGB3). In contrast, 6 proteins were more than 2-fold
downregulated, such as collagen IV alpha2 (COL4A2),
laminin alpha3 (LAMA3) and member B of C-type lectin
domain family 3 (CLEC3B).
TNC and VCAN gene expression, as well as domain
EDA of the FN, were individually analyzed in ILD patients
(Figure 2A). There was a significant increase of TNC and
VCAN gene expression in fibrotic lungs (IPF and cHP)Figure 1 cDNA microarray of ECM proteins reveals genes that are mo
represents gene expression of each protein in IPF lungs (n = 17) versus con
down-regulated in IPF are outside the red line. Detailed values for each procompared with the normal lungs. No significant dif-
ference of FN gene expression was observed between
groups (p = 0.46). Interestingly, IPF and cHP had a
similar increase of TNC, VCAN and FN gene expression,
with no statistical differences between both fibrotic
groups. However, saHP lungs showed lower TNC and
VCAN gene expression than fibrotic lungs (p = 0,032
and p = 0,082, respectively). There was no statistical
association between TNC, VCAN and FN gene ex-
pression with age, sex or smoking history. On the
other hand, these three glycoprotein gene expressions
were statistically correlated among one another, and
this relationship was stronger between TNC and VCAN
(Figure 3).
The upregulation of TNC synthesis in IPF and cHP
was confirmed by the evaluation of TNC protein lungre than 2-fold up- and down-regulated in IPF. Scatter plot
trol lungs (n = 7). Genes that are more than 2-fold up- or
tein are included in Additional file 1.
Figure 2 Glycoprotein synthesis in lung fibrosis. A) TNC, VCAN and FN gene expression in IPF (n = 17), cHP (n = 5), saHP (n = 4) and control
lungs (n = 7). The bottom, middle band and top of the box are the first quartile, median and third quartile, respectively. TNC was significantly
increased in IPF and cHP lungs compared with control (*p < 0.05) and saHP lungs (#p < 0.05). VCAN was higher in IPF and cHP compared with
control lungs (*p < 0.05), and this increase was also significantly different in cHP compared with saHP lungs (#p < 0.05). No significant differences
among groups were found in FN gene expression. B) Western-blotting showing an increase of TNC protein in IPF and cHP lungs compared with
normal and saHP lungs. IPF: idiopathic pulmonary fibrosis, cHP: chronic hypersensitivity pneumonitis, saHP: subacute hypersensitivity pneumonitis,
TNC: tenascin C, VCAN: versican, FN: fibronectin.
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almost undetectable in normal or saHP lungs. IPF and
cHP samples showed different levels of TNC, always
higher than saHP samples (Figure 2B). No relationship
was found between TNC levels and UIP radiological
pattern, FVC or DLCO values at diagnosis (data not
shown). Interestingly, the level of TNC in cHP samples
was associated with the content of fibroblastic foci, how-
ever, there was not a clear relationship between the % of
fibroblastic foci and the level of TNC in IPF lungs
(p = 0,96). Furthermore, TNC levels were correlated with a
significant decrease of %FVC change over 24 weeks in
cHP patients (r = 0.29, p < 0.05). The highest levels of TNC
also associated a %FVC decline after 24 weeks in IPF cases,
however the correlation was not statistically significant
(r = 3.1, p = 0.06).Figure 3 Relationship among TNC, VCAN and FN gene expression. Pe
TNC (r = 0.755, p = 0.001), B) FN and VCAN (r = 0.59, p = 0.001), C) FN and TLocalization of tenascin C, versican and fibronectin in
lung tissue
While TNC localization in the normal lung was un-
detectable (Additional file 2), a well-defined pattern for
TNC expression was observed in histological samples
with UIP (Figure 4A-B). TNC was specifically detected
in the fibroblastic foci with a protein gradient deposition
and it was more intense in subepithelial areas. Moreover,
in these lungs a thin subepithelial TNC expression was
also observed in those regions where a few spindle
shaped alpha smooth muscle actin (α-sma) positive cells
(myofibroblast) were present, but no typical fibroblastic
foci were observed (Figure 4B). VCAN expression was
identified, associated with the elastic components in
normal and pathological lungs (Additional file 2). In
IPF and cHP patients, there was an increased amountarson correlation shows a strong association between A) VCAN and
NC (r = 0.35, p = 0.01). TNC: tenascin C, VCAN: versican, FN: fibronectin.
Figure 4 IHC distribution of TNC, VCAN and FN in fibrotic lungs. A) Immunohistochemical study shows a strong deposition of TNC in
fibroblastic foci of IPF lungs, with more intensity in the subepithelial area. VCAN and FN are present in these fibroblastic foci, although both
glycoproteins are present in other interstitial areas; B) A higher magnification of IPF lungs show myofibroblast rich areas (“early fibroblastic foci”,
pointed with asterisk) where TNC deposition is also present; C) cHP lungs that showed some fibroblastic foci had TNC, VCAN and FN deposition
following a similar pattern than in IPF lungs; α-sma positive cells with spindle shaped morphology localize myofibroblast. H/E: hematoxilin/eosin,
TNC: tenascin C, VCAN: versican, FN: fibronectin, α-sma: alpha-smooth muscle actin.
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foci. Its deposition was homogenous in the foci area
(Figure 4A and 4C). FN was usually found in the
inner layer of vascular walls in normal and patho-
logical lungs, indicating uniformity throughout the
lung (Additional file 2). In IPF and cHP, FN expression
was also observed in fibroblastic foci, and this staining
was more intensive in the subepithelial region, following a
similar distribution to TNC (Figure 4A and 4C).
In saHP lungs, where no FFs were present, few and
specific areas of these glycoproteins were observed;
TNC and FN were only localized in the largest lympho-
cytic aggregates with a reticular pattern. In those saHP
lungs that had some histological organizing pneumonia
areas, TNC was also deposited in the intraluminal
polypoid fibrous structures. However, neither VCAN nor
FN was present in these areas (Figure 4D).In vitro fibroblast TNC synthesis
In order to evaluate constitutive and induced TNC syn-
thesis, cultured lung fibroblasts from both normal tissue
and IPF patients were studied. As shown in Figure 5A,
fibroblasts from IPF lungs had higher levels of TNC and
α-sma gene expression compared to fibroblasts from
normal lungs. TNC gene expression in both normal and
fibrotic fibroblasts was increased after 24 h of TGF-β
treatment, while α-sma gene expression was earlier in-
duced. TNC induced a non-significant increase of α-sma
gene expression in fibroblasts after 4 h of its addition,
although no effect was observed at 24 h. Next, fibrotic
fibroblast protein TNC synthesis was analyzed by Western
Blot after 24 h and 48 h of TGF-β treatment (Figure 5B).An increase of TNC protein and α-sma was observed in
treated cells compared to untreated ones, supporting the
data found in the gene expression (Figure 5B).Discussion
The results of this study show that IPF lungs present a
defined ECM glycoprotein pattern that differs from in-
flammatory interstitial (saHP) and normal lungs, but this
protein profile is similar to other lung fibrotic disorders
such as cHP. A better understanding of the proteome
and the global gene expression of fibrotic lungs could be
the clue to find specific markers involved in lung fibrotic
process [14,15]. It has been reported that the ECM pro-
teins play a key role in the maintenance of architecture
and correct lung repair after any tissue injury, and an
imbalance among these proteins could trigger the pro-
gression of a variety of ILD [16]. The expression of the
specific proteins that form the fibrotic ECM is still a
matter of discussion. In this regard, we focused on the
ECM glycoproteins that were highly upregulated in fibrotic
lungs compared with the normal tissue. Some of these
increased ECM proteins, such as TNC and VCAN, had
been involved in tissue remodeling and, specifically, in dif-
ferent lung diseases that imply an altered wound healing
[6,8,9]. The present study demonstrates that TNC gene
expression is correlated with versican and fibronectin, and
its deposition is colocalized in the same fibroblastic foci,
which are thought to represent ECM active areas of the
altered wound healing in UIP [2]. An abnormally high
deposition of TNC was previously described in lung
tissue and plasma/serum of very different interstitial
lung diseases; usual interstitial pneumonia (UIP), cryptogenic
Figure 5 TNC synthesis in lung fibroblasts. A) TNC and α-sma
gene expression in control and IPF fibroblasts, under different
conditions; (Black) basal, (Light Gray) TNC treatment and (Black Gray)
TGF-β1 treatment (at 4 and 24 h). An increase in basal and induced
TNC synthesis by TGF-β1 at 24 h was observed in IPF fibroblasts.
α-sma gene expression was induced by TNC and TGF-β1 at 4 h,
although the effect of TNC was not significant. B) IPF fibroblasts after
TGF-β1 treatment (24 h and 48 h) showed a progressive increase of
TNC and α-sma synthesis.
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interstitial pneumonia [17-19]. However, this is the first
time that TNC synthesis has been evaluated together with
other glycoproteins in IPF lungs, and it has also been
compared to other fibrotic (cHP) and non-fibrotic ILD
(saHP), as well as to normal lungs. The specific and strong
deposition of TNC in fibroblastic foci of UIP lungs con-
trasted to the small amount of TNC in inflammatory
active areas of saHP, and this difference was confirmed by
the study of protein and gene expression. Furthermore,
our data also show that the increase of TNC was also
observed in cHP, the fibrotic HP subgroup that implies
high mortality, indicating that this increase of TNC is not
specifically for IPF patients. Interestingly, the present re-
sults demonstrate that TNC gene expression is signifi-
cantly different between cHP and saHP. This difference in
the gene profile could contribute to the different outcome
found between both subtypes of the same entity.
It has already been suggested that increased TNC
expression in patients with UIP pattern is associated
with a shortened lifespan [17]. Moreover, the relation-
ship between TNC level and the poor outcome of other
tissue remodeling entities, such as heart failure after
myocardial lesion, has been previously described [20].
Despite the limitations of the present study concerning
to the lack of a long-term follow-up and the total number
of cases, the present results suggest a correlation between
the lung levels of TNC and the progression of lung fibro-
sis (%FVC decline over 6 months), meanly in cHP pa-
tients. However, prospective studies with a higher number
of patients are required in order to test the relationship
between TNC and IPF outcome.
The relationship between VCAN and TNC has not been
clearly understood yet, although a tissue co-localization of
these glycoproteins has been detected in the peritumoural
stroma in breast cancer [8]. However, Suwiwat and col. [8]
showed that increased TNC levels, but not versican levels,
were related to increased tumor size, higher grade and
stage of breast carcinoma. Versican overexpression has
been poorly studied in interstitial lung diseases, however
its effects on motility, invasion and metastasis have been
widely reported in cancer [9,21-23]. Focusing on TNC
protein structure, Day and col. demonstrated that the G3
region of versican showed fairly low affinities for fibronec-
tin type III repeats (3–5) region of TNC, so both proteins
presented an interaction between each other [23]. Our
results indicate a strong positive correlation between TNC
and VCAN gene expression, however, the correlation
between TNC and FN is not so evident. Further studies
are needed to understand the exact interaction between
these proteins and their effects on lung fibrosis.
Previous studies described several functional roles of
TNC in the experimental fibrotic process. TNC-null mice
were protected from interstitial fibrosis in bleomycin-
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responsiveness [24]. Furthermore, TNC triggers fibrin
accumulation by downregulation of tissue plasminogen
activator in this experimental model of lung fibrosis [25].
A possible consequence of increased TNC expression
during injury is the recruitment of fibroblasts to the
site of tissue damage [26]. Induced migration and adhesion
in pancreatic cancer cells [6] and in α-sma cells [27] has
also been described. Nagaharu and col. [28] demonstrated
that this protein has also been involved in EMT-like
changes in human breast cancer cells. The present results
show an interstitial TNC deposition in adjacent areas to
α-sma positive cells, mainly in subepithelial regions of
typical fibroblastic foci and initial spaces of fibrotic acti-
vity. Moreover, an upregulation of α-sma gene expression
in fibrotic fibroblasts was observed after TNC treatment.
Taking together these data suggests a putative role of
TNC in the formation of the fibroblastic foci, a relevant
morphologic marker of the fibrotic stage.
The release and regulation of TNC depends in part on
fibroblasts. Fibrotic fibroblasts constitutively synthesized
more TNC than normal fibroblasts. As it was previously
described for dermal fibroblasts and primary human
lung fibroblasts [19,29], TGF-β1 induced synthesis of
TNC, which has been shown to be mediated by SMAD or
p38 MAPK pathway activation. The capacity of TGF-β1
to induce TNC synthesis has been also reported in culture
alveolar epithelial cells (A549) [30]. Altogether, these data
suggest that TNC upregulation could be the consequence
of a pro-fibrotic molecular microenvironment after a lung
injury in the active areas of altered wound healing.
Conclusions
The ECM glycoproteins, TNC and VCAN, were highly
expressed in lungs where pathologies evolved with al-
tered wound healing, leading to fibrosis. The expression,
localization and synthesis of TNC in fibrotic lungs sug-
gest that it could be a relevant glycoprotein for fibro-
blastic foci activity and fibrosis progression. Further
studies are needed in order to understand its effects and
the possible benefits of its regulation in IPF. An alte-
ration of ECM protein homeostasis after lung injury
would play a crucial role in parenchymal lung diseases,
and these proteins could be a key factor for treatment in
order to inhibit this pathological process.Additional files
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